• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

inVentive, IMS or Cegedim









I like the TargetRx promo audit data the best. It was a good product before, due to the variety of specialties and settings covered. It has only become better since they integrated the ImpactRx data into their product.

Cegedigm data is good. I like the IMS data the least.